30 results about "Leucine+Isoleucine" patented technology

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ω-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

The invention discloses an ecological compound coagulant, its production method and the use in producing colorful vegetable / fruit bean curd. The ecological compound coagulant contains the flowing components in weight parts: 20-30 weight parts of CaSO4, 0.8-1.5 weight parts of glucono-delta-lactone, 0.1-0.2 weight parts of calcium hydrogen phosphate, 0.05-0.1 weight parts of potassium tartrate, 0.3-0.4 weight parts of sodium hydrogen phosphate, 0.8-0.9 weight parts of fumaric acid, 0.15-0.25 weight parts of corn starch and 0.8-0.9 weight parts of surfactant. The surfactant is selected from lysine, methionine, tryptophan, phenylalanine, valine, leucine, isoleucine, threonine, and a combination thereof. The coagulant ensures elasticity, chewiness and smooth mouthfeel of bean curd, and prevents the bean curd to be broken and cracked during the slicing or shredding process.

A compound amino acid composition for protecting the kidney contains glycine, alpha-alanine, threonine, serine, leucine, isoleucine, proline, etc, and can be used to prepare the medicine in the form injection, powder, tablet, or capsule for treating the acute renal dysfunction caused by cisplatin medicines and ischemia. Its advantage is high curative effect.

The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).

The invention discloses an alcohol dehydrogenase mutant and a use thereof. The alcohol dehydrogenase mutant is shown in the formula (1) and / or (2). (1) Phenylalanine at 147th of an amino acid sequenceshown in the formula of SEQ ID NO.1 is replaced by leucine, isoleucine, methionine or cysteine. (2) Alanine at 202th of the amino acid sequence shown in the formula of SEQ ID NO.1 is replaced with leucine, isoleucine or valine. A semi-rational design is used to modify the alcohol dehydrogenase LkADH derived from Lactobacillus kefir so that a plurality of alcohol dehydrogenase mutants are obtained. The alcohol dehydrogenase mutant has the characteristics of high enzyme activity, can efficiently catalyze t-butyl 6-chloro-3, 5-dicarbonylcaproate to prepare t-butyl (S)-6-chloro-5-hydroxy-3-carbonylcaproate and has a great significance for the production of statin drug intermediates.

The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).

The present invention provides nonamer peptides derived from fibroblast activation protein α (FAPα) for the treatment of solid tumors. These peptides specifically bind to HLA, defined by an IC50 value of less than about 50 μM, induce a T cell response in a subject, wherein position No. 2 of said nonamer peptide is leucine (L), isoleucine (I) or methionine (M), and position No. 9 of said nonamer peptide is leucine (L), valine (V) or isoleucine (I). Further, a composition comprising a nonamer peptide and methods for the prophylactic and therapeutic treatment are provided.

Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.

The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided. The compound of formula (I) has the structure shown below, where -R6 and -R7 are each together with the carbonyl group and nitrogen alpha to the carbon to which it is attached an amino acid residue, except that R6 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a phenylalanine, leucine or valine residue and / or -R7 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a leucine, iso-leucine, phenylalanine, threonine, valine or nor-valine residue, and -T, -A1, -A2, -A3 and -R10 are as discussed in the application:

The invention discloses an antibacterial peptide LJ-2 and an application thereof. The amino acid sequence of the antibacterial peptide LJ-2 is as follows: the amino acid sequence of the antibacterialpeptide LJ-2 is shown in the specification: arginine, arginine, valine, leucine, arginine, isoleucine, leucine, lysine, histidine, histidine, glutamine, glycine, leucine, isoleucine, arginine, asparagine, leucine and leucine; the antibacterial peptide LJ-2 has good antibacterial activity on gram-positive bacteria, gram-negative bacteria and fungi, and has the advantages of low hemolysis, heat resistance, salt resistance, acid and alkali resistance and repeated freeze thawing resistance. Therefore, the antibacterial peptide LJ-2 disclosed by the invention has a wide application prospect in thefields of anti-infective drug preparation, animal husbandry development, human disease prevention and treatment, food preservation, detergents, cosmetics and the like.

The invention relates to a direct vat set acetic acid bacteria leavening agent and a preparation method and application thereof. The direct vat set acetic acid bacteria leavening agent is prepared from acetic acid bacteria and a protective agent, the protective agent comprises skimmed milk powder and amino acid, and the amino acid comprises leucine, isoleucine and valine. According to the invention, the skimmed milk powder, leucine, isoleucine and valine are creatively combined as a protective agent for acetic acid bacteria, and the four components cooperate with each other and have synergistic interaction, so that the destructive effect of ice crystal formation on thalli and the damage of dehydration drying on thalli and enzyme activity in the freeze-drying process can be reduced, the activity of acetic acid bacteria is better protected, the survival rate in the freeze-drying process is improved, and the viable count of acetic acid bacteria in the prepared leavening agent is increased. The direct vat set acetic acid bacteria leavening agent provided by the invention has important application value in preparation of fermented beverages or fermented seasonings.

The invention discloses a method for preparing calcium 3-methyl-2-oxovalerate. The method comprises the following steps of: dripping diethyl oxalate into an alcoholic solution of sodium alkoxide; dripping 2-methyl butyraldehyde, keeping the temperature, stirring, adding an alkali solution, regulating the acid after heat insulation is ended, extracting, and adding a certain amount of water into an extracting solution; adding the alkali solution to regulate the pH, dripping an aqueous solution of calcium chloride for salifying to obtain the coarse 3-methyl-2-oxovalerate product; and refining the coarse 3-methyl-2-oxovalerate product in a mixed solvent of purified water and organic solvent, and obtaining the refined 3-methyl-2-oxovalerate product. The process is mild in reaction conditions, easy to operate, fewer in steps, high in yield and high in quality, the adopted raw materials are cheap and basically do not cause pollution, waste gas and lots of waste residues are avoided, and the method is suitable for industrial production.

The embodiments herein provide a composition and a method of synthesizing a composition comprising an aliphatic amino acid biosynthesis inhibitor having an antifungal activity. The composition comprises 2-oxo-2H-chromen-7-yl propiolate, diethyl-hex-2-en-4-yne-dioate and dinonyl-hex-2-en-4-yne-dioate. The composition inhibits a biosynthesis of an aliphatic amino acid in a fungal biological system. The aliphatic amino acid is selected from a group consisting of leucine, isoleucine and valine. The composition is used with a concentration of 0-200 μg / ml. The method comprises mixing solutions of dicyclohexylcarbodiimide (DCC) and Dimethylaminopyridine (DMAP) with alcohol, acetylene carboxylic acid and dichloromethane to obtain a mixture which is stirred filtered and washed with ether. The solvents are evaporated to obtain a residue that is dissolved in dichloromethane and stirred with a catalyst. The extra solvents are evaporated to obtain the derivative compound and purified by silica gel column chromatography.

The invention belongs to the technical field of biological medicine, and discloses anti-tumor grifola frondosa glycoprotein as well as a preparation method and application thereof. The protein content of the anti-tumor grifola frondosa glycoprotein is 54.0 + / -3.0%, the polysaccharide content of the anti-tumor grifola frondosa glycoprotein is 20.3 + / -2.0%, the weight-average molecular weight of the anti-tumor grifola frondosa glycoprotein is 17.5 kDa, and the monosaccharide composition and the molar ratio of fucose to glucosamine hydrochloride to galactose to glucose to mannose to galacturonic acid to glucuronic acid are 2.4: 0.8: 3.9: 72.3: 7.7: 3.2: 9.6. The amino acids are composed of alanine, glycine, threonine, valine, leucine, isoleucine, proline, asparaginic acid, phenylalanine, tyrosine and glutamic acid. The grifola frondosa glycoprotein disclosed by the invention has the effects of enhancing immune response of a tumor body and inhibiting in-vivo growth of breast cancer through in-vivo verification.

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.

The invention discloses an alcohol dehydrogenase mutant and a use thereof. The alcohol dehydrogenase mutant is shown in the formula (1) and / or (2). (1) Phenylalanine at 147th of an amino acid sequenceshown in the formula of SEQ ID NO.1 is replaced by leucine, isoleucine, methionine or cysteine. (2) Alanine at 202th of the amino acid sequence shown in the formula of SEQ ID NO.1 is replaced with leucine, isoleucine or valine. A semi-rational design is used to modify the alcohol dehydrogenase LkADH derived from Lactobacillus kefir so that a plurality of alcohol dehydrogenase mutants are obtained. The alcohol dehydrogenase mutant has the characteristics of high enzyme activity, can efficiently catalyze t-butyl 6-chloro-3, 5-dicarbonylcaproate to prepare t-butyl (S)-6-chloro-5-hydroxy-3-carbonylcaproate and has a great significance for the production of statin drug intermediates.

The present invention designs and synthesizes a fluorescent sensor capable of single and selective recognition of L-arginine, which first uses 4,4´-biphenol and hexamethylenetetramine as substrates in a trifluoroacetic acid solvent The reaction produces 4,4´-biphenol derivatives; and then reacts in absolute ethanol with isoniazid and 4,4´-biphenol derivatives as substrates to obtain the target fluorescent sensor FINH. DMSO‑H in fluorescent sensors 2 O solution, respectively add L-glycine, L-alanine, L-valine, L-leucine, L-isoleucine, L-methionine, L-proline, L- Tryptophan, L-Serine, L-Tyrosine, L-Cysteine, L-Phenylalanine, L-Asparagine, L-Glutamine, L-Threonine, L-Asparagine amino acid, L-glutamic acid, L-lysine, L-arginine and L-histidine, and found that only the addition of L-arginine can enhance the fluorescence of the fluorescent sensor FINH, thus realizing Highly sensitive and single selective recognition of L-arginine.

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.

The invention discloses a preparation method of branched chain amino acid chelated copper. The preparation method of the branched chain amino acid chelated copper comprises the following steps: adding raw materials into a high-pressure reaction kettle; heating the high-pressure reaction kettle to obtain a reaction solution; putting the reaction solution into a crystallization kettle for cooling crystallization; centrifuging and drying the crystallization liquid; crushing the dried product, and sterilizing the crushed product in a sterilization box; packaging to obtain the food-grade branched chain amino acid copper, wherein the branched chain amino acid is food-grade valine, leucine, isoleucine and a mixture of the food-grade valine, leucine and isoleucine. The preparation method has the beneficial effects that branched chain amino acids are food-grade valine, leucine, isoleucine and a mixture thereof, a copper source is food-grade copper hydroxide, copper oxide and a mixture of the food-grade copper hydroxide and copper oxide, stirring, mixing and high-temperature heating are carried out in a high-pressure reaction kettle, cooling crystallization, centrifugal drying and sterilization operations are adopted for post-treatment, the process is fine and perfect, and the quality of the obtained branched chain amino acid chelated copper is high.

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.

The invention discloses an application of a plasma metabolite in the aspect of diagnosing the severity of Parkinson's disease, and particularly relates to an application of the plasma metabolite in preparing a detection reagent or a detection substance for diagnosing the severity of Parkinson's disease. The plasma metabolite comprises plasma branched-chain amino acid and / or aromatic amino acid, the branched-chain amino acid is selected from one or a combination of three of leucine, isoleucine and valine, and the aromatic amino acid is tyrosine and / or phenylalanine. Plasma is taken as a sample, a biological sample is easy to obtain, simple and convenient to collect, large in quantity, low in price and short in detection period, the severity of the PD disease can be judged by detecting plasma markers, and the method is a reliable, efficient, convenient and fast novel method and has good application prospects in treatment and prognosis of PD patients.

The invention belongs to the field of veterinary medicine, and discloses compound amino acid soluble powder which comprises 5-15% of compound amino acid, 10-35% of an inclusion agent, 5-10% of a stabilizer, 2-5% of a flavoring agent and 35-78% of a soluble filler, the compound amino acids comprise lysine, methionine, tryptophan, arginine, threonine, histidine, leucine, isoleucine, phenylalanine, valine, glycine and proline; the invention also discloses a preparation method of the compound amino acid soluble powder. The preparation method is used for preparing the compound amino acid soluble powder, the stability and solubility of the compound amino acid can be improved through the inclusion agent, the preparation process is simple and feasible, and large-scale industrial production is facilitated.

The invention provides a method for simultaneously detecting contents of leucine, isoleucine and valine in blood. The method comprises the following steps: respectively detecting at least three standard solutions by using a high performance liquid chromatography tandem mass spectrometer and a PFP chromatographic column to obtain a chromatogram of each standard solution containing a standard substance and an internal standard substance of each branched chain amino acid with the known concentration; carrying out fitting based on the chromatogram of each standard solution to obtain a standard curve equation of each branched chain amino acid; adding the mixed internal standard working solution into a blood sample obtained by treating at least 0.2 mL of to-be-detected blood, adding a protein precipitation reagent, carrying out vortex mixing, carrying out centrifuging to obtain a supernatant, diluting the supernatant, carrying out vortex mixing again, and then taking the supernatant to obtain a to-be-detected sample; detecting the to-be-detected sample to obtain a chromatogram; and then calculating the contents of leucine, isoleucine and valine in the blood sample according to the chromatogram of the to-be-detected sample and each standard curve equation. The sample pretreatment is simple; the time is saved; and the operation becomes rapid.

A method for treating and / or preventing osteoarthritis includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

A method for treating a tendon injury includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.

The present invention discloses a pearl-derived functional peptide and a use thereof. An amino acid sequence of the functional peptide is methionine-isoleucine-isoleucine-leucine-leucine-cysteine-serine-leucine-leucine (MIILLCSLL). The functional peptide has a good function of scavenging free radicals in organisms, an antioxidant function and a melanin cytochrome synthesis inhibitory activity, andthus the functional peptide can be used for preparing radical scavengers, antioxidants and cosmetic raw materials having a whitening function.